PREFACE
Thank you Annie (Rimoin) for those introductory comments. I can assure those tuned
in that some of those stories are actually true. And, I am proof that there is no
age discrimination in the ASTMH.
The Society has been my main professional home for five decades. This year has been
like no other in our history—the COVID-19 pandemic has challenged us in every way.
We have responded to the assaults on science through writing for our Journal and for
other journals, joining like-minded societies with statements to the press and live
interviews, and appealing directly to decision-makers.
Advocacy for global health research and control programs in poor countries has been
led by our CEO Karen Goraleski. She, with our great staff and partners, has been performing
miracles. Thanks team TropMed. And a big thanks to our board of directors, who set
the standards high and are major advocates for what we do.
The biggest challenge has been to have this virtual meeting. I thank Dan Bausch and
Stephanie Yanow, chair and associate chair of the Scientific Program Committee, and
Lyn Maddox, vice president for meetings, for this feat, plus those understanding folks
in Toronto whom we hope to see in the future.
Most dear to me is my family. My wife, Vicki—nurse, lawyer, chaplain, house manager,
and fellow-traveler—has had good reason to serve me with divorce papers for frequent
abandonment. She hasn’t...yet! My son, Matthew, and daughter, Johanna, and their spouses,
Rachel and Tomer, are also stars with rich international histories and horizons. Thanks
to them for constant support and guidance, and for their wisdom in raising kind, curious,
and generous children of their own. May my grandchildren, Sebastian, Aviva, Leora,
Eden, Arielle, and Felix get into good trouble on their own.
Now, for the main event. First, I would like all those who have worked on and supported
the smallpox eradication program to stand—wherever you are. You are the heroes I honor
today, who were celebrated yesterday in the smallpox symposium and mentioned by Dr.
Tedros Adhanom Ghebreyesus, Director General of the World Health Organization, in
his opening remarks.
2020 President Joel G. Breman, MD, DTPH, FASTMH
INTRODUCTION
2020 marks 40 years since the World Health Assembly accepted the 1979 conclusion of
the Global Commission for the Certification of Smallpox Eradication that the dread
disease had been eradicated.
1
It is fitting that we reflect on the history and conduct of the eradication program,
focusing on Africa. Not only is Africa where the first and last cases of the disease
were recorded, but where some of the unique control and eradication strategies and
tactics were discovered and deployed. The control of the COVID-19 pandemic will be
dependent on many of the principles and practices used in smallpox eradication, another
reason to examine our past.
SMALLPOX IN AFRICA
The Pharaoh Ramses V died in 1157 BCE. He has the dubious distinction of being the
first known patient with smallpox, caused by variola virus. His mummified face had
a set of pustules when the corpse was unwrapped and photographed in the early 1900s
(Figure 1).
2
Variola virus needs a critical number of humans to continue circulating, as there
is no nonhuman reservoir of smallpox.
3
The fertile crescent between the Tigris and Euphrates rivers was one of the most dense
population centers in the world before the time of Christ—the others being in the
Ganges River basin in the Indian subcontinent and between the Yellow and Yangtze rivers
in present day China.
Figure 1.
Ramses V, 1157 BCE. Source: WHO.
Over the next 1800 years, the disease remained in these population-dense areas, because
smaller towns and hamlets could not sustain continual interhuman transmission. About
700 CE, with the rise of Islam in the Middle East and the spread of religion and trade
across North Africa and south into sub-Saharan Africa, smallpox and other diseases
took hold.
COLONIZATION
Over the next several hundred years, the great African kingdoms prospered. They fostered
great art, architecture, and political stability. Figure 2 shows what may have been
smallpox lesions from a statue in Mali dated thirteenth century (Figure 2).
Figure 2.
Smallpox in Art. Terra cotta statue, 13th century, Mali empire. Metropolitan Museum
of Art, NYC. Photo provided by Kevin Tervala, Baltimore Museum of Art.
By the late 1400s and well into the 1800s, the European powers arrived and established
territorial extensions of their own kingdoms. First Portugal, then France, Belgium,
Britain, Germany, Holland, and Spain. This influence lasts to this day.
DISEASES AND DISEASE CONTROL
The colonizers were clear in their goals: to establish outposts for expediting their
commercial interests. This included subjugating the locals—often by a divide and conquer
strategy. Divisions of territory were made geographically in Europe, often without
great attention to ethnic boundaries (Figure 3).
Figure 3.
European colonial possessions in Africa, from 1600s to 1922. Figure provided by Kevin
Tervala of Baltimore Museum of Art.
The expatriate communities concentrated along the coastlines in the capitals and in
other large cities. These areas benefitted preferentially from public health measures
which, beginning in the late 1800s, included vaccination against smallpox with partially
effective liquid vaccines.
During the colonial period, the foreign military served as senior clinicians and public
health supervisors. Civil servants and military officers trained in tropical diseases
in Lisbon, Antwerp, London, Liverpool, Marseille, Bordeaux, and elsewhere provided
the leadership and staffing of rural outposts. It was soon found that these isolated
rural populations were afflicted with many medical conditions requiring attention.
4
SLEEPING SICKNESS IN THE CONGO BASIN AND OTHER AREAS OF SUB-SAHARAN AFRICA
The great campaign against sleeping sickness led by Eugene Jamot of France started
in the Cameroons in the 1920s and slowly went north, village by village. Jamot trained
illiterate microscopists to look for trypanosomes in the tissue taken from the nodules
in the necks or cerebrospinal fluid of suspected patients with sleeping sickness.
5
They also saw much smallpox.
Similar mobile teams were deployed in Anglophone West Africa focusing also on onchocerciasis,
schistosomiasis, and leprosy while also giving smallpox vaccinations.
6
Liquid smallpox vaccine was not heat stable. Vaccine success rates reflected by pustules
on the arm were often less than 50%.
7,8
Despite hundreds of thousands of smallpox vaccinations given in West and Central Africa—many
more than the censused population numbers—periodic epidemics of smallpox raged in
Africa. The real numbers were 10–100 times higher because of incomplete reporting.
WHO PROGRAMS
In 1948, the WHO was formed with altruistic goals to develop health policies, establish
disease surveillance systems, and promote control and elimination programs, of which
malaria control relying on DDT for indoor house spraying was the most prominent activity.
SMALLPOX ELIMINATION
In 1959, the Soviet delegation introduced a resolution for a smallpox eradication
program to the World Health Assembly.
3
For the next 8 years, little progress was made: few staff and funds came to the WHO
for smallpox work. In 1967, an intensified eradication program began after another
smallpox eradication resolution was endorsed by the assembly. About then, U.S. President
Lyndon Johnson supported smallpox eradication efforts in West and Central Africa as
part of the global program.
9
The WHO requested that the director of the global smallpox program come from the United
States—the country that had raised the resolution for an intensified program. D. A.
Henderson of the CDC was chosen as the leader of the Smallpox Eradication Unit.
10
STATUS OF SMALLPOX—1967
One of the first things done by the Smallpox Unit in Geneva was to look at the quality
of vaccine being used by countries. It was found in 1967 that only 10% of the laboratories
producing smallpox vaccines met standards for potency, stability, and purity (Figure
4). Two reference laboratories—Connaught in Canada and the Rijks Institute in Bilthoven,
the Netherlands—tested products from 59 vaccine manufacturers.
3
Figure 4.
The vaccine supply crisis.
Seven countries of the 20 in the West and Central African program were among those
with the highest incidence of smallpox in the world (Table 1).
11
Table 1
Countries with the Highest Smallpox Rates, 1967
Country
Cases/100,000 population
Sierra Leone
68.3
Guinea
40.2
Benin (Dahomey)
32.1
Niger
31.7
Togo
17.3
India
15.3
Tanzania
13.4
Indonesia
11.7
Pakistan
10.4
Congo (Brazzaville)
9.0
Nigeria
7.8
Brazil
5.1
Foege et al.
11
Bold = Countries in the West and Central African Smallpox Eradication-Measles Control
Program.
Measles vaccine had been developed in the United States in the early 1960s at Merck,
and the Minister of Health of Burkina Faso (then Upper Volta) visited the United States
in the 1960s and invited the U.S. government to test feasibility of deployment of
this vaccine in West Africa. After 2 years of field technology testing by CDC staff
supported by the USAID, and country negotiation, the West and Central African smallpox–measles
program was conceived and implemented. I lived in Guinea for 2 years and Burkina Faso
for another 4 years during this program, and then in Geneva working on the final phases
of eradication from 1977 to 1980.
TECHNOLOGIES AND INNOVATIONS
Several scientific, technical, and managerial innovations led to the success of this
program.
1.
Freeze-dried vaccines: Both smallpox and measles vaccines were sent from the manufacturers
to the field in heat stable, freeze-dried powder form along with diluent.
12
2.
Administration of vaccine: The Ped-O-Jet injector gun was used to inject the vaccine
directly into the skin. An intradermal nuzzle was used for smallpox vaccine and a
subcutaneous nozzle for measles.
3.
Groups at risk: All persons were given smallpox vaccine as all were at risk. Children
aged 6 months to 5 years were given measles vaccine. In Guinea, each team averaged
2,000 persons vaccinated a day per team over 2 years.
13,14
Ped-O-Jet was effective when large numbers of persons could be assembled, as in Brazil
and West and Central Africa. Toward the end of the West and Central African Program,
the bifurcated needle was introduced into all of Africa and the endemic countries.
This modification of a sewing machine needle allowed a drop of the vaccine to be caught
between the prongs when dipped into the vaccine bottle. This allowed a great saving
in vaccine. The procedure could be taught in a few minutes to virtually anyone, and
the needles sterilized easily at night. Success rates were more than 95%.
3,14
4.
Strategy: The strategy when the West and Central African program began was to vaccinate
at least 80% of the population—the original goal of the global program. It was believed
that this level of coverage could result in herd immunity.
However, during the vaccine shortage in eastern Nigeria in 1967–1968 during the Biafran
civil war, a CDC contract missionary, Bill Foege, former EIS officer, vaccinated only
family members and close contacts of patients with smallpox. Other contacts at risk
were vaccinated and put under surveillance. The cluster of outbreaks in eastern Nigeria
completely melted. This approach became known as “selective ring vaccination” and
“surveillance containment.”
15
Emphasis was now put on aggressively finding every case of smallpox and stopping its
spread. Epidemiological indices were used to find and contain cases—particularly seasonality.
When the number of outbreaks and cases was lowest, during the rainy season, this was
the best time to go to areas of high suspicion. Mass vaccination continued, but resources
and publicity were now aimed toward surveillance and containment. An early track,
trace, and cross-notification strategy was used. The last smallpox case was detected
in Nigeria in May 1970.
11
5.
Diagnostic and research support: Supportive laboratory diagnosis and Orthopoxvirus
research was built into the program from an early stage, first focusing on vaccine
quality, but later on diagnostic conundrums.
In May 1971, a patient with a typical smallpox-like eruption was detected in the Democratic
Republic of Congo, then Zaire, 10 months after the last smallpox case had occurred.
WHO Poxvirus Collaborating laboratories in Moscow and Atlanta confirmed the diagnosis
as monkeypox virus, an agent that had been the cause of outbreaks in animals in North
American and European zoos. Over the next decade, several countries in West and Central
Africa reported cases of human monkeypox. This newly detected disease in humans did
not appear to transmit avidly from person to person.
16,17
Smallpox vaccine protects against monkeypox, but immunity has waned since vaccination
stopped in 1982 after eradication.
18
Few longitudinal ecological studies of monkeypox have occurred. One rope squirrel
with an eruption was found near a monkeypox outbreak, yet the natural history of this
disease remains to be clarified.
Several recent large outbreaks of human monkeypox have been reported in Nigeria and
DRC, as we heard at the smallpox symposium. We are now facing a decision on whether
smallpox vaccine should again be used in areas where monkeypox is endemic.
19
6.
Operational innovations: The use of operations officers—managerial experts—was a major
innovation in the West and Central African program. These persons were conversant
with epidemiology and control, and became experts in logistics, communications, transport,
personnel, and equipment—especially proper storage of vaccines. Management with surveillance
was key to eradication.
7.
Surveillance: Knowing what works and does not work in a timely, regular manner is
now accepted by public health programs since smallpox. The WHO Weekly Epidemiological
Record was used to transmit information on progress in each program.
10
And the CDC had their own periodic summary for the West and Central African program,
including progress in measles activities.
8.
Field innovations: The best ideas throughout the program came from the field, not
from headquarters.
3
They were village-by-village searches for cases; feeding patients in their homes under
guard; smallpox identification cards for searching in schools, villages, and camps;
screening at festivals and the annual pilgrimage to Mecca; smallpox rumor registers;
a monetary reward for reporting confirmed smallpox cases; detailed protocols for reporting
and investigating cases; having petty cash funds in the hands of field-workers to
hire local searchers and guards; moving staff from country to country when political
winds changed, as occurred between Ethiopia and Somalia in the mid-1970s; and using
Peace Corps workers as case detection agents and field supervisors.
EXPANSION OF ELIMINATION
Whereas the West and Central African program was maturing, great progress was being
made elsewhere. In the Americas, only Brazil and Argentina had disease. South America
was the first continent to be certified smallpox-free by an independent commission.
The major challenges remained with the Indian subcontinent and eastern Africa.
The big hurdle in India was convincing national and state health authorities that
the surveillance containment strategy – including track, trace, isolate, vaccinate,
report, and cross notify – was more effective than mass vaccination.
Village searches turned up thousands of outbreaks that had been unknown or unrecorded!
At one time, more than 150,000 field-workers in India alone were hunting smallpox.
A detailed containment protocol for use at the local level was used. The last outbreak
occurred in Ethiopia and then Somalia in 1976–1977, countries that were at war over
land. Cases were occurring among nomads in the Ogaden desert, and moved into Somalia.
Before containment occurred, more than 3,000 cases were identified and contained.
3
The last naturally transmitted case occurred in Merca, coastal Somalia, on October
26, 1977. The last patients with naturally transmitted smallpox were Rahima Banu in
Bangladesh, 1975, who had Variola major, and Ali Maaow Maalin, Somalia, 1977 with
V. minor.
SMALLPOX LESSONS FOR COVID CONTROL
There are many differences between COVID and smallpox. Coronaviruses are RNA viruses;
as such they mutate, facilitating genetic and geographic tracking. A new mutant has
been detected in England and South Africa and can be expected to spread worldwide.
The variant is more transmissible between humans than the first isolates. This facilitates
tracking the geographic spread. Seven coronaviruses are known to cause human disease.
SARS-CoV-2 is believed to have come from an animal, perhaps as a bat virus transferred
to another animal, and then with spillover to humans.
20
Although there are many orthopoxviruses, variola, a DNA virus, is classified into
major and minor. The major differences are in clinical and epidemiological presentation.
There are public health lessons from smallpox that should be applied to public health
control. The incubation period is 5–10 days for COVID-19 and 7–17 days for smallpox.
Both are respiratory diseases transmitted mainly by large droplets. Important is the
secondary attack rate among susceptibles.
21
Considering the R
o
, for COVID-19, we are now seeing two–three, compared with three–six for smallpox
and about 12 for measles.
There was no smallpox spread from asymptomatic persons to those in the incubation
period. COVID does transmit during the incubation period.
Both conditions now have Food and Drug Administration (FDA)-approved treatments. During
the program, we had no specific treatment for smallpox. With the specter of bioterrorism
for smallpox, tecovirimat was recently approved by the FDA. Remdesivir is approved
for COVID-19, but only shortens clinical illness, not mortality.
For smallpox, we had strong central leadership at the WHO, applying a public health
model, with flexibility to change the model when new evidence accrued. We had a detailed
operational plan. Each country adapted the plan based on local conditions; the new
surveillance containment strategy using ring vaccination was central to the plan.
High-quality vaccine, other supplies, and equipment usually came through a supply
chain that was carefully managed centrally. Personnel from more than 70 countries
worked as international civil servant leaders in endemic countries, serving the goals
of the eradication program, rather than their own national agendas.
3
Without this leadership and clarity, the program would have failed. The importance
of international cooperation must be emphasized.
In closing, let me return to African innovations for COVID-19 control. Control measures,
initiated by African countries, have muted the spread—particularly the rigorous implementation
of case tracking, along with other mitigation measures. Nigeria, Uganda, Rwanda, and
South Africa, among others, have developed highly successful methods in finding case
contacts, testing them and taking measures to limit spread if they are positive. These
countries had extensive experience establishing tracking systems for the Ebola outbreaks
that have hit Africa since 1976—and also for polio, Lassa fever, Guinea worm, HIV/AIDS,
and measles outbreaks.
23,24
The innovations applied in Africa first resulted in the eradication of smallpox. Those
being developed by African colleagues today will help us control COVID-19 and other
perils now and in the future.
Thank you.